{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T03:32:36Z","timestamp":1791689556245,"version":"4.3.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.4158\/ep161322.or","type":"journal-article","created":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T17:44:42Z","timestamp":1470159882000},"page":"1369-1376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effects of Long-Term Alendronate Treatment on a Large Sample of Pediatric Patients with Osteogenesis Imperfecta"],"prefix":"10.1016","volume":"22","author":[{"given":"Fang","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doudou","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibo","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/EP161322.OR_bb0010","first-page":"CD002010","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","volume":"3","author":"Phillipi","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.4158\/EP161322.OR_bb0015","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","article-title":"Osteogenesis imperfecta","volume":"387","author":"Forlino","year":"2016","journal-title":"Lancet"},{"key":"10.4158\/EP161322.OR_bb0020","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrendo.2011.81","article-title":"New perspectives on osteogenesis imperfecta","volume":"14","author":"Forlino","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.4158\/EP161322.OR_bb0025","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00223-012-9588-3","article-title":"Recent advances in osteogenesis imperfecta","volume":"90","author":"Cundy","year":"2012","journal-title":"Calcif Tissue Int"},{"key":"10.4158\/EP161322.OR_bb0030","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(04)16051-0","article-title":"Osteogenesis imperfecta","volume":"363","author":"Rauch","year":"2004","journal-title":"Lancet"},{"key":"10.4158\/EP161322.OR_bb0035","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jbmr.2410","article-title":"Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials","volume":"30","author":"Hald","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP161322.OR_bb0040","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00198-015-3216-9","article-title":"Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study","volume":"27","author":"Otaify","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP161322.OR_bb0045","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1210\/jc.2010-0636","article-title":"Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study","volume":"96","author":"Ward","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP161322.OR_bb0050","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/jbmr.2567","article-title":"Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: skeletal findings during follow up throughout the growing years","volume":"30","author":"Palomo","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP161322.OR_bb0055","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S0140-6736(13)61091-0","article-title":"Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Bishop","year":"2013","journal-title":"Lancet"},{"key":"10.4158\/EP161322.OR_bb0060","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00198-011-1658-2","article-title":"Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists","volume":"23","author":"Bradbury","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP161322.OR_bb0065","first-page":"3049","article-title":"Benefit of infusions with ibandronate treatment in children with osteogenesis imperfect","volume":"124","author":"Li","year":"2011","journal-title":"Chin Med J (Engl)"},{"key":"10.4158\/EP161322.OR_bb0070","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/jbmr.2567","article-title":"Intravenous Bisphosphonate Therapy of Young Children with Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years","volume":"30","author":"Palomo","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP161322.OR_bb0075","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/ajmg.a.36545","article-title":"Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment","volume":"164","author":"Van Dijk","year":"2014","journal-title":"Am J Med Genet A"},{"key":"10.4158\/EP161322.OR_bb0080","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jocd.2014.01.003","article-title":"Dual-energy X-ray absorptiometry interpretation and reporting in children and adolescents: the revised 2013 ISCD Pediatric Official Positions","volume":"17","author":"Crabtree","year":"2014","journal-title":"J Clin Densitom"},{"key":"10.4158\/EP161322.OR_bb0085","doi-asserted-by":"crossref","first-page":"e82098","DOI":"10.1371\/journal.pone.0082098","article-title":"Bone mineral density of the spine in 11,898 Chinese infants and young children: a cross-sectional study","volume":"8","author":"Xu","year":"2013","journal-title":"PLoS One"},{"key":"10.4158\/EP161322.OR_bb0090","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.bone.2010.12.013","article-title":"Normative data and percentile curves for dual energy X-ray absorptiometry in healthy Indian girls and boys aged 5\u201317 years","volume":"48","author":"Khadilkar","year":"2011","journal-title":"Bone"},{"key":"10.4158\/EP161322.OR_bb0095","first-page":"487","article-title":"Height and weight standardized growth charts for Chinese children and adolescents aged 0 to 18 years","volume":"47","author":"Li","year":"2009","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"10.4158\/EP161322.OR_bb0100","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1210\/jc.2011-0385","article-title":"Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline","volume":"96","author":"Holick","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP161322.OR_bb0105","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3109\/09513590.2013.813468","article-title":"Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis","volume":"29","author":"Serrano","year":"2013","journal-title":"Gynecol Endocrinol"},{"key":"10.4158\/EP161322.OR_bb0110","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","article-title":"Bisphosphonates: the first 40 years","volume":"49","author":"Russell","year":"2011","journal-title":"Bone"},{"key":"10.4158\/EP161322.OR_bb0115","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP161322.OR_bb0120","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1359\/jbmr.081238","article-title":"Alendronate treatment of the Brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation","volume":"24","author":"Uveges","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP161322.OR_bb0125","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(04)16101-1","article-title":"Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study","volume":"363","author":"Sakkers","year":"2004","journal-title":"Lancet"},{"key":"10.4158\/EP161322.OR_bb0130","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s00774-014-0618-2","article-title":"Beneficial effects of intravenous pamidronate treatment in children with osteogenesis imperfecta under 24 months of age","volume":"33","author":"Kusumi","year":"2015","journal-title":"J Bone Miner Metab"},{"key":"10.4158\/EP161322.OR_bb0135","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1385\/JCD:4:2:147","article-title":"Sex differences in bone mass acquisition during growth: the Fels Longitudinal Study","volume":"4","author":"Nguyen","year":"2001","journal-title":"J Clin Densitom"},{"key":"10.4158\/EP161322.OR_bb0140","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3109\/17453674.2013.831321","article-title":"Bone mineral density in developing children with osteogenesis imperfecta: a longitudinal study with 9 years of follow-up","volume":"84","author":"Kok","year":"2013","journal-title":"Acta Orthop"},{"key":"10.4158\/EP161322.OR_bb0145","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/jbmr.2486","article-title":"Osteotomy Healing in Children with Osteogenesis Imperfecta Receiving Bisphosphonate Treatment","volume":"30","author":"Anam","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP161322.OR_bb0150","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1359\/JBMR.040814","article-title":"Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate","volume":"19","author":"Munns","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP161322.OR_bb0155","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/01.bpo.0000152940.10487.c9","article-title":"Bone healing in children with osteogenesis imperfecta treated with bisphosphonates","volume":"25","author":"Pizones","year":"2005","journal-title":"J Pediatr Orthop"},{"key":"10.4158\/EP161322.OR_bb0160","first-page":"1","article-title":"Teriparatide as a systemic treatment for lower extremity nonunion fractures: a case series","volume":"8","author":"Mancilla","year":"2014","journal-title":"Endocr Pract"},{"key":"10.4158\/EP161322.OR_bb0165","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00198-014-2737-y","article-title":"Adult Brtl\/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength","volume":"25","author":"Sinder","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP161322.OR_bb0170","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/jor.22636","article-title":"Sclerostin monoclonal antibody enhanced bone fracture healing in an open osteotomy model in rats","volume":"32","author":"Suen","year":"2014","journal-title":"J Orthop Res"},{"key":"10.4158\/EP161322.OR_bb0175","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1359\/JBMR.051006","article-title":"Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta","volume":"21","author":"DiMeglio","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP161322.OR_bb0180","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1210\/jc.2004-2054","article-title":"Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I","volume":"90","author":"Ward","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP161322.OR_bb0185","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bone.2016.02.013","article-title":"Effect of high-dose vitamin D supplementation on bone density in youth with osteogenesis imperfecta: A randomized controlled trial","volume":"86","author":"Plante","year":"2016","journal-title":"Bone"},{"key":"10.4158\/EP161322.OR_bb0190","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.bone.2008.11.009","article-title":"Tracking of bone mass from childhood to adolescence and factors that predict deviation from tracking","volume":"44","author":"Foley","year":"2009","journal-title":"Bone"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20356263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20356263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:00:50Z","timestamp":1761516050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20356263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S1530891X20356263"],"URL":"https:\/\/doi.org\/10.4158\/ep161322.or","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Long-Term Alendronate Treatment on a Large Sample of Pediatric Patients with Osteogenesis Imperfecta","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP161322.OR","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}